Click here for a description of the charts and data table
Please tell us if you are using this feature and what you think!
ChEMBL ligand: CHEMBL223228 (DMP-266, (-)-efavirenz, Efavirenz, Efavirenz teva, Efavirenzum, L-743726, NSC-742403, Stocrin, Sustiva, Sustiva 600, Viraday) |
---|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
There should be some charts here, you may need to enable JavaScript!
|
DB | Assay description | Assay Type | Standard value | Standard parameter | Original value | Original units | Original parameter | Reference |
---|---|---|---|---|---|---|---|---|
ABCG2/ATP-binding cassette sub-family G member 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL5393] [GtoPdb: 792] [UniProtKB: Q9UNQ0] | ||||||||
ChEMBL | Inhibition of human ABCG2 expressed in dog MDCK-II-BCRP cells mediated pheophorbide A efflux preincubated with PhA followed by compound addition and measured after 60 mins by flow cytometry | B | 4.69 | pIC50 | 20600 | nM | IC50 | Eur J Med Chem (2022) 237: 114346-114346 [PMID:35483322] |
CYP46A1/Cholesterol 24-hydroxylase in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4523510] [GtoPdb: 1373] [UniProtKB: Q9Y6A2] | ||||||||
ChEMBL | Binding affinity to recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli in presence of substrate by UV-spectrophotometric method | B | 4.99 | pKd | 10200 | nM | Kd | J Med Chem (2020) 63: 6477-6488 [PMID:31617715] |
ChEMBL | Binding affinity to recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli in absence of substrate at 24 degC by stopped-flow spectrophotometric method | B | 5.3 | pKd | 5000 | nM | Kd | J Med Chem (2020) 63: 6477-6488 [PMID:31617715] |
ChEMBL | Binding affinity to recombinant human C-terminal 4His-tagged CYP46A1 delta(2 to 50) mutant expressed in Escherichia coli in absence of substrate by UV-spectrophotometric method | B | 6.1 | pKd | 800 | nM | Kd | J Med Chem (2020) 63: 6477-6488 [PMID:31617715] |
Envelope glycoprotein gp160 in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1293311] [UniProtKB: Q6QLK5] | ||||||||
ChEMBL | Binding affinity to HIV1 cYTA48P envelope glycoprotein gp120 infected in human TZM-b1 cells assessed as induction of conformational changes measured after 48 hrs | B | 8.46 | pIC50 | 3.5 | nM | IC50 | Bioorg Med Chem Lett (2019) 29: 719-723 [PMID:30665681] |
Human immunodeficiency virus type 1 reverse transcriptase in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL247] [UniProtKB: Q72547] | ||||||||
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N mutant | B | 5.52 | pKi | 3000 | nM | Ki | J Med Chem (2007) 50: 5412-5424 [PMID:17910429] |
ChEMBL | Inhibition of HIV1 recombinant reverse transcriptase K103N mutant-DNA binary complex expressed in Escherichia coli BL21 | B | 5.8 | pKi | 1600 | nM | Ki | J Med Chem (2009) 52: 840-851 [PMID:19140683] |
ChEMBL | Inhibition of HIV1 recombinant free reverse transcriptase K103N mutant expressed in Escherichia coli BL21 | B | 5.82 | pKi | 1500 | nM | Ki | J Med Chem (2009) 52: 840-851 [PMID:19140683] |
ChEMBL | Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer K103N mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting | B | 6.14 | pKi | 730 | nM | Ki | Bioorg Med Chem (2011) 19: 5794-5802 [PMID:21903401] |
ChEMBL | Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer K103N/Y181C mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting | B | 6.24 | pKi | 580 | nM | Ki | Bioorg Med Chem (2011) 19: 5794-5802 [PMID:21903401] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 K103N mutant after 30 mins by liquid scintillation counting | B | 6.24 | pKi | 580 | nM | Ki | Bioorg Med Chem (2013) 21: 1150-1158 [PMID:23357038] |
ChEMBL | Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution Y188L | B | 6.52 | pKi | 300 | nM | Ki | J Med Chem (2001) 44: 305-315 [PMID:11462972] |
ChEMBL | Inhibition of HIV1 recombinant reverse transcriptase K103N mutant-DNA-dNTP ternary complex expressed in Escherichia coli BL21 | B | 6.7 | pKi | 200 | nM | Ki | J Med Chem (2009) 52: 840-851 [PMID:19140683] |
ChEMBL | Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution K103N | B | 6.8 | pKi | 160 | nM | Ki | J Med Chem (2001) 44: 305-315 [PMID:11462972] |
ChEMBL | Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 K103N mutant expressed in Escherichia coli JM109 | B | 6.8 | pKi | 160 | nM | Ki | J Med Chem (2009) 52: 1224-1228 [PMID:19170521] |
ChEMBL | Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 Y181I mutant expressed in Escherichia coli JM109 | B | 6.82 | pKi | 150 | nM | Ki | J Med Chem (2009) 52: 1224-1228 [PMID:19170521] |
ChEMBL | Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution Y181I | B | 6.82 | pKi | 150 | nM | Ki | J Med Chem (2001) 44: 305-315 [PMID:11462972] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 K103N/Y181C mutant after 30 mins by liquid scintillation counting | B | 6.85 | pKi | 140 | nM | Ki | Bioorg Med Chem (2013) 21: 1150-1158 [PMID:23357038] |
ChEMBL | Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 L100I mutant expressed in Escherichia coli JM109 | B | 6.92 | pKi | 120 | nM | Ki | J Med Chem (2009) 52: 1224-1228 [PMID:19170521] |
ChEMBL | Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution L1001 | B | 6.92 | pKi | 120 | nM | Ki | J Med Chem (2001) 44: 305-315 [PMID:11462972] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 L100I mutant after 30 mins by liquid scintillation counting | B | 7.1 | pKi | 80 | nM | Ki | Bioorg Med Chem (2013) 21: 1150-1158 [PMID:23357038] |
ChEMBL | Inhibition of DNA-dependent DNA polymerase activity of HIV1 reverse transcriptase p66/p66 homodimer Y181C mutant using activated DNA and [alpha-32P]dATP after 30 mins by liquid scintillation counting | B | 7.1 | pKi | 80 | nM | Ki | Bioorg Med Chem (2011) 19: 5794-5802 [PMID:21903401] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 V106A mutant after 30 mins by liquid scintillation counting | B | 7.3 | pKi | 50 | nM | Ki | Bioorg Med Chem (2013) 21: 1150-1158 [PMID:23357038] |
ChEMBL | Inhibition of HIV-1 Mutant HIV-1 RT enzymes containing the single amino acid substitution V106A | B | 7.4 | pKi | 40 | nM | Ki | J Med Chem (2001) 44: 305-315 [PMID:11462972] |
ChEMBL | Inhibition of HIV-1 wild-type RT | B | 7.52 | pKi | 30 | nM | Ki | J Med Chem (2001) 44: 305-315 [PMID:11462972] |
ChEMBL | Inhibition of wild type HIV1 3B reverse transcriptase | B | 7.52 | pKi | 30 | nM | Ki | J Med Chem (2007) 50: 5412-5424 [PMID:17910429] |
ChEMBL | Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase p66/p51 expressed in Escherichia coli JM109 | B | 7.52 | pKi | 30 | nM | Ki | J Med Chem (2009) 52: 1224-1228 [PMID:19170521] |
ChEMBL | Inhibition of wild type HIV1 free reverse transcriptase | B | 7.52 | pKi | 30 | nM | Ki | J Med Chem (2009) 52: 840-851 [PMID:19140683] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase-DNA binary complex | B | 7.52 | pKi | 30 | nM | Ki | J Med Chem (2009) 52: 840-851 [PMID:19140683] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 Y181C mutant after 30 mins by liquid scintillation counting | B | 7.52 | pKi | 30 | nM | Ki | Bioorg Med Chem (2013) 21: 1150-1158 [PMID:23357038] |
ChEMBL | Binding affinity towards L100I mutant HIV-1 reverse transcriptase (as per ref 10 in the article) | B | 7.6 | pKi | 25 | nM | Ki | Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403] |
ChEMBL | Binding affinity towards L100I mutant HIV-1 reverse transcriptase (as per ref 10 in the article) | B | 7.77 | pKi | 17 | nM | Ki | Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403] |
ChEMBL | Non-competitive inhibition of wild type HIV1 reverse transcriptase p66/p51 after 30 mins by liquid scintillation counting | B | 8 | pKi | 10 | nM | Ki | Bioorg Med Chem (2013) 21: 1150-1158 [PMID:23357038] |
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N mutant by SPA assay | B | 8.07 | pKi | 8.5 | nM | Ki | Bioorg Med Chem Lett (2010) 20: 4328-4332 [PMID:20609585] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase-DNA-dNTP ternary complex | B | 8.4 | pKi | 4 | nM | Ki | J Med Chem (2009) 52: 840-851 [PMID:19140683] |
ChEMBL | Binding affinity towards wild type HIV-1 reverse transcriptase (as per ref 10 in the article) | B | 8.52 | pKi | 3 | nM | Ki | Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403] |
ChEMBL | Binding affinity towards wild type HIV-1 reverse transcriptase (as per ref 10 in the article) | B | 8.52 | pKi | 3 | nM | Ki | Bioorg Med Chem Lett (2001) 11: 2799-2802 [PMID:11597403] |
ChEMBL | Inhibition of HIV1 reverse transcriptase | B | 8.53 | pKi | 2.93 | nM | Ki | J Med Chem (2019) 62: 4851-4883 [PMID:30516990] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase by SPA assay | B | 9.4 | pKi | 0.4 | nM | Ki | Bioorg Med Chem Lett (2010) 20: 4328-4332 [PMID:20609585] |
ChEMBL | Inhibition of HIV1 reverse transcriptase Y181C mutant by SPA assay | B | 9.52 | pKi | 0.3 | nM | Ki | Bioorg Med Chem Lett (2010) 20: 4328-4332 [PMID:20609585] |
ChEMBL | Inhibition of ribonuclease H activity of wild type Human immunodeficiency virus 1 reverse transcriptase | B | 4 | pIC50 | >100000 | nM | IC50 | Eur J Med Chem (2012) 50: 216-229 [PMID:22361685] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase K103N mutant assessed as reduction in enzyme activity | B | 4.7 | pIC50 | >20000 | nM | IC50 | J Med Chem (2014) 57: 9945-9957 [PMID:25418038] |
ChEMBL | Inhibition of HIV1 wild-type reverse transcriptase K103N mutant using [3H]dTTP by scintillation counting | B | 4.7 | pIC50 | >20000 | nM | IC50 | Eur J Med Chem (2014) 80: 101-111 [PMID:24769348] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of recombinant HIV-1 p66/p51 reverse transcriptase K103N mutant assessed as inhibition of [3H]dTTP incorporation using poly(rA)/oligo(dT) as templates incubated for 15 mins by MicroBeta scintillation counting method | B | 4.7 | pIC50 | >20000 | nM | IC50 | Eur J Med Chem (2020) 208: 112696-112696 [PMID:32883642] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66 K103N mutant associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation counting analysis | B | 4.7 | pIC50 | >20000 | nM | IC50 | J Med Chem (2017) 60: 6528-6547 [PMID:28628334] |
ChEMBL | Inhibitory concentration against HIV-1 mutant reverse transcriptase (K103R) | B | 5.68 | pIC50 | 2100 | nM | IC50 | J Med Chem (2005) 48: 3858-3873 [PMID:15916438] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase | B | 5.82 | pIC50 | 1520 | nM | IC50 | Bioorg Med Chem (2011) 19: 5924-5934 [PMID:21930388] |
ChEMBL | Inhibition of recombinant HIV1 reverse transcriptase K103N/Y181C double mutant using DIG-dUTP/biotin-dUTP/dTTP assessed as suppression of biotin-dUTP incorporation after 1 hr by ELISA | B | 5.85 | pIC50 | 1420 | nM | IC50 | J Med Chem (2016) 59: 7991-8007 [PMID:27541578] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase Y188L mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis | B | 5.92 | pIC50 | 1200 | nM | IC50 | Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060] |
ChEMBL | Inhibition of HIV1 3B reverse transcriptase p66/p51 K103N/Y181C mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry | B | 5.92 | pIC50 | 1200 | nM | IC50 | Bioorg Med Chem (2016) 24: 2476-2485 [PMID:27112451] |
ChEMBL | Inhibition of DNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant by gel-based primer extension assay | B | 6.04 | pIC50 | 910 | nM | IC50 | Antimicrob Agents Chemother (2010) 54: 2401-2408 [PMID:20308384] |
ChEMBL | Inhibition of HIV1 reverse transcriptase | B | 6.1 | pIC50 | 800 | nM | IC50 | Bioorg Med Chem Lett (2006) 16: 3430-3433 [PMID:16632349] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of HIV1 subtype B reverse transcriptase M230L mutant by filter-based filtration assay | B | 6.13 | pIC50 | 740 | nM | IC50 | Antimicrob Agents Chemother (2010) 54: 2401-2408 [PMID:20308384] |
ChEMBL | Inhibition of HIV-1 BH10 recombinant reverse transcriptase K103N mutant expressed in Escherichia coli assessed as incorporation of [32P]GTP into poly(rA)/oligo(dT) as template primer | B | 6.13 | pIC50 | 740 | nM | IC50 | Bioorg Med Chem (2016) 24: 3006-3022 [PMID:27234889] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 K103N mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry | B | 6.14 | pIC50 | 730 | nM | IC50 | Bioorg Med Chem (2016) 24: 2476-2485 [PMID:27112451] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of Human immunodeficiency virus 1 reverse transcriptase Lys103Asn mutant | B | 6.17 | pIC50 | 680 | nM | IC50 | Eur J Med Chem (2012) 50: 216-229 [PMID:22361685] |
ChEMBL | Inhibition of HIV1 reverse transcriptase Tyr181Cys mutant-associated RNA-dependent DNA polymerase activity after 30 mins | B | 6.17 | pIC50 | 680 | nM | IC50 | Eur J Med Chem (2015) 93: 452-460 [PMID:25728026] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase K103N mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis | B | 6.2 | pIC50 | 630 | nM | IC50 | Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060] |
ChEMBL | Inhibition of HIV1 Reverse transcriptase p51/p66 K103N mutant after 30 mins using alpha-[32P]dATP by liquid scintillation counting | B | 6.24 | pIC50 | 580 | nM | IC50 | Medchemcomm (2013) 4: 1443-1451 |
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N mutant expressed in Escherichia coli BL21 (DE3) using [alpha-32P]dATP after 30 mins by liquid scintillation counting | B | 6.24 | pIC50 | 580 | nM | IC50 | Medchemcomm (2013) 4: 741-748 |
ChEMBL | Inhibition of HIV1 reverse transcriptase Y181I mutant by RNA-dependent DNA polymerase activity assay | B | 6.3 | pIC50 | 500 | nM | IC50 | Bioorg Med Chem (2010) 18: 1702-1710 [PMID:20097079] |
ChEMBL | Inhibitory concentration against HIV-1 mutant reverse transcriptase (K103N+Y181C) | B | 6.3 | pIC50 | 500 | nM | IC50 | J Med Chem (2005) 48: 3858-3873 [PMID:15916438] |
ChEMBL | Inhibition of wild type HIV-1 reverse transcriptase assessed as reduction of biotin-dUTP incorporation into protein using ABTS as substrate incubated for 1 hrs by ELISA analysis | B | 6.32 | pIC50 | 480 | nM | IC50 | Eur J Med Chem (2022) 238: 114471-114471 [PMID:35640327] |
ChEMBL | Inhibition of HIV1 HXB2 reverse transcriptase K103N mutant activity by primer extension assay | B | 6.38 | pIC50 | 414 | nM | IC50 | Antimicrob Agents Chemother (2010) 54: 4451-4463 [PMID:20660667] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase Y181I mutant assessed as reduction in enzyme activity | B | 6.4 | pIC50 | 400 | nM | IC50 | J Med Chem (2014) 57: 9945-9957 [PMID:25418038] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66 Y181I mutant associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation counting analysis | B | 6.4 | pIC50 | 400 | nM | IC50 | J Med Chem (2017) 60: 6528-6547 [PMID:28628334] |
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N mutant RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate | B | 6.4 | pIC50 | 400 | nM | IC50 | J Med Chem (2012) 55: 6634-6638 [PMID:22712652] |
ChEMBL | Inhibition of HIV1 wild-type reverse transcriptase Y181I/Y181C mutant using [3H]dTTP by scintillation counting | B | 6.4 | pIC50 | 400 | nM | IC50 | Eur J Med Chem (2014) 80: 101-111 [PMID:24769348] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase Y181I/Y181C mutant assessed as reduction in enzyme activity | B | 6.4 | pIC50 | 400 | nM | IC50 | J Med Chem (2014) 57: 9945-9957 [PMID:25418038] |
ChEMBL | Inhibition of HIV1 RT Y188L mutant | B | 6.42 | pIC50 | 380 | nM | IC50 | J Med Chem (2005) 48: 7153-7165 [PMID:16279773] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of HIV1 reverse transcriptase K103N mutant | B | 6.44 | pIC50 | 364 | nM | IC50 | J Med Chem (2009) 52: 1219-1223 [PMID:19175319] |
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N/Y181C double mutant using poly (A)/oligo (dT)15 as template/primer assessed as decrease in biotin-dUTP incorporation after 1 hr by ELISA | B | 6.44 | pIC50 | 360 | nM | IC50 | Bioorg Med Chem (2018) 26: 2051-2060 [PMID:29559197] |
ChEMBL | Inhibition of HIV1 reverse transcriptase Lys103Asn mutant-associated RNA-dependent DNA polymerase activity after 30 mins | B | 6.55 | pIC50 | 280 | nM | IC50 | Eur J Med Chem (2015) 93: 452-460 [PMID:25728026] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase L100I mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis | B | 6.57 | pIC50 | 270 | nM | IC50 | Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060] |
ChEMBL | Inhibition of recombinant wild type HIV-1 His-tagged reverse transcriptase p66/p51 expressed in Escherichia coli JM109 using poly(rA)/oligo(dT)16 as template/primer incubated for 40 mins by pico-green based spectrofluorometric analysis | B | 6.59 | pIC50 | 260 | nM | IC50 | Eur J Med Chem (2020) 185: 111874-111874 [PMID:31735575] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 L100I mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry | B | 6.6 | pIC50 | 250 | nM | IC50 | Bioorg Med Chem (2016) 24: 2476-2485 [PMID:27112451] |
ChEMBL | Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase G190A mutant by filter-based filtration assay | B | 6.67 | pIC50 | 216 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 4667-4672 [PMID:19704127] |
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N mutant by RNA-dependent DNA polymerase activity assay | B | 6.7 | pIC50 | 200 | nM | IC50 | Bioorg Med Chem (2010) 18: 1702-1710 [PMID:20097079] |
ChEMBL | Inhibition of recombinant HIV-1 BH10 reverse transcriptase using D38/[32P]25PGA as template-primer incubated for 5 mins in presence of DTT followed by dTTP addition and measured after 15 to 30 sec by nucleotide incorporation assay | B | 6.74 | pIC50 | 180 | nM | IC50 | Bioorg Med Chem (2021) 30: 115927-115927 [PMID:33352387] |
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis | B | 6.77 | pIC50 | 170 | nM | IC50 | Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311] |
ChEMBL | Inhibition of HIV1 RT K103N mutant | B | 6.8 | pIC50 | 160 | nM | IC50 | J Med Chem (2005) 48: 7153-7165 [PMID:16279773] |
ChEMBL | Inhibition of HIV1 RT Y181I mutant | B | 6.82 | pIC50 | 150 | nM | IC50 | J Med Chem (2005) 48: 7153-7165 [PMID:16279773] |
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N/Y181C mutant expressed in Escherichia coli BL21 (DE3) using [alpha-32P]dATP after 30 mins by liquid scintillation counting | B | 6.85 | pIC50 | 140 | nM | IC50 | Medchemcomm (2013) 4: 741-748 |
ChEMBL | Inhibition of HIV1 Reverse transcriptase p51/p66 K103N/Y181C mutant after 30 mins using alpha-[32P]dATP by liquid scintillation counting | B | 6.85 | pIC50 | 140 | nM | IC50 | Medchemcomm (2013) 4: 1443-1451 |
ChEMBL | Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase Y181C mutant by filter-based filtration assay | B | 6.9 | pIC50 | 126 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 4667-4672 [PMID:19704127] |
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N/Y181C double mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis | B | 6.92 | pIC50 | 120 | nM | IC50 | Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311] |
ChEMBL | Inhibition of HIV1 RT L100I mutant | B | 6.92 | pIC50 | 120 | nM | IC50 | J Med Chem (2005) 48: 7153-7165 [PMID:16279773] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase L100I mutant assessed as reduction in enzyme activity | B | 6.92 | pIC50 | 120 | nM | IC50 | J Med Chem (2014) 57: 9945-9957 [PMID:25418038] |
ChEMBL | Inhibition of recombinant HIV1 reverse transcriptase using poly rA:dT as template/primer after 1 hr by ELISA | B | 6.92 | pIC50 | 120 | nM | IC50 | Bioorg Med Chem Lett (2013) 23: 6593-6597 [PMID:24239481] |
ChEMBL | Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase G190A mutant by filter-based filtration assay | B | 6.95 | pIC50 | 112 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 4667-4672 [PMID:19704127] |
ChEMBL | Inhibition of HIV-1 NL4-3 reverse transcriptase by RT-PCR analysis | B | 6.96 | pIC50 | 110 | nM | IC50 | Eur J Med Chem (2023) 246: 114981-114981 [PMID:36481598] |
ChEMBL | Inhibition of HIV1 reverse transcriptase Y188L mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis | B | 7 | pIC50 | 100 | nM | IC50 | Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase V106A mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis | B | 7 | pIC50 | 100 | nM | IC50 | Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase by filter-based filtration assay | B | 7.03 | pIC50 | 93 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 4667-4672 [PMID:19704127] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of wild type recombinant HIV-1 His-tagged p66/p51 reverse transcriptase assessed as inhibition of [3H]dTTP incorporation using poly(rA)/oligo(dT) as templates incubated for 15 mins by MicroBeta scintillation counting method | B | 7.1 | pIC50 | 80 | nM | IC50 | Eur J Med Chem (2020) 208: 112696-112696 [PMID:32883642] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)10:1 and [3H]-dTTP substrate | B | 7.1 | pIC50 | 80 | nM | IC50 | J Med Chem (2012) 55: 6634-6638 [PMID:22712652] |
ChEMBL | Inhibition of HIV1 wild-type reverse transcriptase using [3H]dTTP by scintillation counting | B | 7.1 | pIC50 | 80 | nM | IC50 | Eur J Med Chem (2014) 80: 101-111 [PMID:24769348] |
ChEMBL | Inhibition of HIV1 reverse transcriptase L100I mutant expressed in Escherichia coli BL21 (DE3) using [alpha-32P]dATP after 30 mins by liquid scintillation counting | B | 7.1 | pIC50 | 80 | nM | IC50 | Medchemcomm (2013) 4: 741-748 |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase assessed as reduction in enzyme activity | B | 7.1 | pIC50 | 80 | nM | IC50 | J Med Chem (2014) 57: 9945-9957 [PMID:25418038] |
ChEMBL | Inhibition of HIV1 Reverse transcriptase p51/p66 L100I mutant after 30 mins using alpha-[32P]dATP by liquid scintillation counting | B | 7.1 | pIC50 | 80 | nM | IC50 | Medchemcomm (2013) 4: 1443-1451 |
ChEMBL | Inhibition of HIV1 NL4-3 reverse transcriptase His-tagged p66/p51 associated RNA dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in [3H]dTTP incorporation using poly(rA)/oligo(dT) as template/primer by scintillation counting analysis | B | 7.1 | pIC50 | 80 | nM | IC50 | J Med Chem (2017) 60: 6528-6547 [PMID:28628334] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 Y181C mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry | B | 7.15 | pIC50 | 70 | nM | IC50 | Bioorg Med Chem (2016) 24: 2476-2485 [PMID:27112451] |
ChEMBL | HIV-1 reverse transcriptase inhibitory activity against Asn103 mutant using (poly)rC600*(oligo)dGT as template primer. | B | 7.21 | pIC50 | 61 | nM | IC50 | J Med Chem (1999) 42: 4150-4160 [PMID:10514285] |
ChEMBL | Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells after dialysis | B | 7.22 | pIC50 | 60 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 638-644 [PMID:17116672] |
ChEMBL | Inhibition of HIV1 reverse transcriptase G190A mutant expressed in Escherichia coli BL21 (DE3) using [alpha-32P]dATP after 30 mins by liquid scintillation counting | B | 7.22 | pIC50 | 60 | nM | IC50 | Medchemcomm (2013) 4: 741-748 |
ChEMBL | Inhibition of HIV-1 reverse transcriptase G190A mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis | B | 7.24 | pIC50 | 57 | nM | IC50 | Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060] |
ChEMBL | Inhibition of DNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase by gel-based primer extension assay | B | 7.24 | pIC50 | 57 | nM | IC50 | Antimicrob Agents Chemother (2010) 54: 2401-2408 [PMID:20308384] |
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N mutant in 293T cells | B | 7.27 | pIC50 | 54 | nM | IC50 | Bioorg Med Chem Lett (2006) 16: 3034-3038 [PMID:16527484] |
ChEMBL | Inhibition of HIV1 reverse transcriptase L100I mutant by RNA-dependent DNA polymerase activity assay | B | 7.3 | pIC50 | 50 | nM | IC50 | Bioorg Med Chem (2010) 18: 1702-1710 [PMID:20097079] |
ChEMBL | Inhibition of HIV1 reverse transcriptase V106A mutant expressed in Escherichia coli BL21 (DE3) using [alpha-32P]dATP after 30 mins by liquid scintillation counting | B | 7.3 | pIC50 | 50 | nM | IC50 | Medchemcomm (2013) 4: 741-748 |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 V106A mutant using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry | B | 7.3 | pIC50 | 50 | nM | IC50 | Bioorg Med Chem (2016) 24: 2476-2485 [PMID:27112451] |
ChEMBL | HIV-1 reverse transcriptase inhibitory activity against Ile 100 mutant using (poly)rC600*(oligo)dGT as template primer. | B | 7.3 | pIC50 | 50 | nM | IC50 | J Med Chem (1999) 42: 4150-4160 [PMID:10514285] |
ChEMBL | Inhibition of HIV1 Reverse transcriptase p51/p66 V106A mutant after 30 mins using alpha-[32P]dATP by liquid scintillation counting | B | 7.3 | pIC50 | 50 | nM | IC50 | Medchemcomm (2013) 4: 1443-1451 |
ChEMBL | Inhibition of recombinant wild type HIV1 RT using poly(rA)/oligo(dT)16 as template after 40 mins by spectrofluorometric analysis | B | 7.32 | pIC50 | 48 | nM | IC50 | Eur J Med Chem (2013) 65: 134-143 [PMID:23707918] |
ChEMBL | Inhibitory activity against HIV-1 reverse transcriptase enzyme | B | 7.32 | pIC50 | 48 | nM | IC50 | Bioorg Med Chem Lett (1999) 9: 2805-2810 [PMID:10522695] |
ChEMBL | Inhibitory concentration for 50% inhibition of HIV-1 reverse transcriptase | B | 7.32 | pIC50 | 48 | nM | IC50 | Bioorg Med Chem Lett (2000) 10: 1729-1731 [PMID:10937734] |
ChEMBL | Inhibitory activity against HIV-1 reverse transcriptase | B | 7.32 | pIC50 | 48 | nM | IC50 | Bioorg Med Chem Lett (1999) 9: 3221-3224 [PMID:10576692] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase. | B | 7.32 | pIC50 | 48 | nM | IC50 | Bioorg Med Chem Lett (2001) 11: 1943-1945 [PMID:11459666] |
ChEMBL | Inhibitory activity against HIV-1 reverse transcriptase | B | 7.33 | pIC50 | 47 | nM | IC50 | Bioorg Med Chem Lett (2001) 11: 619-622 [PMID:11266155] |
ChEMBL | Compound was evaluated for the inhibition of HIV-1 Reverse transcriptase | F | 7.33 | pIC50 | 47 | nM | IC50 | J Med Chem (2000) 43: 2019-2030 [PMID:10821714] |
ChEMBL | The compound was evaluated for the inhibition of HIV-1 reverse transcriptase | B | 7.33 | pIC50 | 47 | nM | IC50 | Bioorg Med Chem Lett (2000) 10: 193-195 [PMID:10673109] |
ChEMBL | Tested for inhibitory concentration against HIV-1 non-nucleoside reverse transcriptase | B | 7.33 | pIC50 | 47 | nM | IC50 | Bioorg Med Chem Lett (2001) 11: 211-214 [PMID:11206461] |
ChEMBL | Inhibition of the NNRTI HIV-1 enzyme by 50% using enzyme assay. | B | 7.33 | pIC50 | 47 | nM | IC50 | Bioorg Med Chem Lett (2001) 11: 309-312 [PMID:11212098] |
ChEMBL | Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 assessed as reduction in biotin-labeled dUTP incorporation into DNA using polyr(A) x oligo(dT)16 template/primer hybrid | B | 7.36 | pIC50 | 44 | nM | IC50 | Eur J Med Chem (2015) 97: 1-9 [PMID:25935383] |
ChEMBL | Inhibition of reverse transcriptase activity in HIV1 NL4-3 infected MT4 cells before dialysis | B | 7.38 | pIC50 | 42 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 638-644 [PMID:17116672] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of HIV1 reverse transcriptase Y181C mutant | B | 7.4 | pIC50 | 40 | nM | IC50 | J Med Chem (2009) 52: 1219-1223 [PMID:19175319] |
ChEMBL | Inhibition of HIV1 RT V106A mutant | B | 7.4 | pIC50 | 40 | nM | IC50 | J Med Chem (2005) 48: 7153-7165 [PMID:16279773] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of Human immunodeficiency virus 1 recombinant reverse transcriptase expressed in Escherichia coli using poly(rA)oligo(dT) template primer after 30 min | B | 7.4 | pIC50 | 40 | nM | IC50 | Med Chem Res (2006) 15: 492-510 |
ChEMBL | Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 assessed as reduction in biotin-dUTP incorporation incubated for 40 mins using poly(rA) template and oligo(dT)16 primer by picogreen dye based spectrofluorometry | B | 7.4 | pIC50 | 40 | nM | IC50 | Eur J Med Chem (2017) 140: 383-391 [PMID:28987601] |
ChEMBL | Inhibition of recombinant wild type HIV1 p66/p51 using poly(rA) template/oligo(dT)16 primer after 40 mins by PicoGreen-based spectrofluorometric method | B | 7.42 | pIC50 | 38 | nM | IC50 | Eur J Med Chem (2016) 121: 352-363 [PMID:27267005] |
ChEMBL | Compound was evaluated for its ability to inhibit HIV-1 Reverse Transcriptase in an in vitro enzyme assay | B | 7.42 | pIC50 | 38 | nM | IC50 | Bioorg Med Chem Lett (2001) 11: 1389-1392 [PMID:11378361] |
ChEMBL | Inhibition of HIV1 reverse transcriptase | B | 7.42 | pIC50 | 38 | nM | IC50 | Eur J Med Chem (2016) 108: 455-465 [PMID:26708112] |
ChEMBL | Inhibition of wild-type HIV1 reverse transcriptase p66/p51 after 40 mins by spectrophotometry | B | 7.42 | pIC50 | 38 | nM | IC50 | Bioorg Med Chem (2014) 22: 2535-2541 [PMID:24680058] |
ChEMBL | Inhibition of HIV1 reverse transcriptase | B | 7.42 | pIC50 | 38 | nM | IC50 | J Med Chem (2019) 62: 4851-4883 [PMID:30516990] |
ChEMBL | Inhibition of HIV-1 wild type recombinant reverse transcriptase p66/p51 assessed as RNA-DNA heteroduplex formation using poly(rA) template/oligo(dT)16 primer incubated prior to enzyme addition by spectrofluorometer analysis | B | 7.43 | pIC50 | 37 | nM | IC50 | Medchemcomm (2014) 5: 468-473 |
ChEMBL | Inhibition of recombinant wild type HIV-1 reverse transcriptase p66/p51 expressed in Escherichia coli JM109 using poly(rA)/oligo(dT)16 (1:1.2) as template/primer after 40 mins by spectrofluorometric analysis | B | 7.43 | pIC50 | 37 | nM | IC50 | Bioorg Med Chem (2013) 21: 6477-6483 [PMID:24055077] |
ChEMBL | Inhibition of DNA-dependent DNA polymerase activity of wild-type Human immunodeficiency virus 1 subtype B reverse transcriptase Y181C mutant by filter-based filtration assay | B | 7.44 | pIC50 | 36 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 4667-4672 [PMID:19704127] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 assessed as inhibition of biotin-dUTP incorporation using poly (rA)/oligo(dT)16 as template/primer incubated for 40 mins | B | 7.46 | pIC50 | 35 | nM | IC50 | Eur J Med Chem (2015) 102: 215-222 [PMID:26276435] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase associated RNA-dependent DNA polymerase activity using poly(A)-oligo(dT) as template/primer incubated for 30 mins by multilabel counter plate reader analysis | B | 7.46 | pIC50 | 35 | nM | IC50 | J Med Chem (2021) 64: 8579-8598 [PMID:34106711] |
ChEMBL | Inhibition of GST-tagged recombinant wild type HIV-1 reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 using dTTP as substrate after 40 mins by spectrofluorometric analysis | B | 7.49 | pIC50 | 32 | nM | IC50 | Bioorg Med Chem (2014) 22: 1459-1467 [PMID:24457088] |
ChEMBL | Inhibition of recombinant wild type HIV-1 reverse transcriptase using DNA/RNA as substrate incubated for 40 mins by Pico-green dye based spectrofluorometric analysis | B | 7.52 | pIC50 | 30 | nM | IC50 | J Med Chem (2023) 66: 4755-4767 [PMID:36996328] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of wild type HIV1 subtype B reverse transcriptase by filter-based filtration assay | B | 7.52 | pIC50 | 30 | nM | IC50 | Antimicrob Agents Chemother (2010) 54: 2401-2408 [PMID:20308384] |
ChEMBL | Inhibition of HIV1 reverse transcriptase Y181C mutant expressed in Escherichia coli BL21 (DE3) using [alpha-32P]dATP after 30 mins by liquid scintillation counting | B | 7.52 | pIC50 | 30 | nM | IC50 | Medchemcomm (2013) 4: 741-748 |
ChEMBL | Inhibition of HIV1 Reverse transcriptase p51/p66 Y181C mutant after 30 mins using alpha-[32P]dATP by liquid scintillation counting | B | 7.52 | pIC50 | 30 | nM | IC50 | Medchemcomm (2013) 4: 1443-1451 |
ChEMBL | Inhibition of HIV-1 reverse transcriptase E138K mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis | B | 7.52 | pIC50 | 30 | nM | IC50 | Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase Y181C mutant assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis | B | 7.52 | pIC50 | 30 | nM | IC50 | Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060] |
ChEMBL | Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as decrease in biotin-dUTP incorporation using DIG-labeled dUTP/biotin-labeled dUTP and dTTP as template and viral nucleotides after 1 hr by ELISA | B | 7.52 | pIC50 | 30 | nM | IC50 | ACS Med Chem Lett (2018) 9: 334-338 [PMID:29670696] |
ChEMBL | Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 incubated for 40 mins by picogreen dye-based spectrofluorometric analysis | B | 7.52 | pIC50 | 30 | nM | IC50 | J Med Chem (2019) 62: 11430-11436 [PMID:31714780] |
ChEMBL | Inhibition of recombinant HIV-1 reverse transcriptase p66/p51 incubated for 40 mins by picogreen dye based spectrofluorometric assay | B | 7.52 | pIC50 | 30 | nM | IC50 | Eur J Med Chem (2019) 182: 111603-111603 [PMID:31421633] |
ChEMBL | Inhibition of HIV1 Reverse transcriptase incubated for 30 mins by fluorescence based analysis | B | 7.52 | pIC50 | 30 | nM | IC50 | J Med Chem (2023) 66: 6193-6217 [PMID:37130343] |
ChEMBL | Inhibition of wild type HIV1 p66/p51 reverse transcriptase by spectrofluorometry | B | 7.62 | pIC50 | 24 | nM | IC50 | Bioorg Med Chem (2015) 23: 624-631 [PMID:25537532] |
ChEMBL | Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 pre-incubated with compound before enzyme addition using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry | B | 7.66 | pIC50 | 22 | nM | IC50 | Bioorg Med Chem (2015) 23: 1069-1081 [PMID:25638501] |
ChEMBL | Inhibition of recombinant HIV1 Reverse transcriptase p66/p51 using poly (rA)-oligo (dT) as template primer after 40 mins by spectrofluorometric analysis | B | 7.66 | pIC50 | 22 | nM | IC50 | Bioorg Med Chem (2015) 23: 6587-6593 [PMID:26385446] |
ChEMBL | Inhibition of HIV1 recombinant wild type reverse transcriptase p66/p51 assessed as reduction in biotin deoxyuridine triphosphate (biotin-dUTP) incorporation using poly(rA)/oligo (dT)16 template and primer by spectrofluorometry | B | 7.66 | pIC50 | 22 | nM | IC50 | Bioorg Med Chem (2015) 23: 4248-4255 [PMID:26162497] |
ChEMBL | Inhibition of wild-type HIV1 Reverse transcriptase p66/p51 assessed as relative fluorescence signal after 40 mins | B | 7.66 | pIC50 | 22 | nM | IC50 | Bioorg Med Chem (2015) 23: 3860-3868 [PMID:25907370] |
ChEMBL | Inhibitory concentration against HIV-1 mutant reverse transcriptase (Y181C) | B | 7.7 | pIC50 | 20 | nM | IC50 | J Med Chem (2005) 48: 3858-3873 [PMID:15916438] |
ChEMBL | Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(rA)-oligo(dT) as template/primer and digoxigenin-/biotin-labeled dUTP nucleotides incubated for 1 hr | B | 7.7 | pIC50 | 20 | nM | IC50 | Eur J Med Chem (2014) 87: 52-62 [PMID:25240095] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase using poly (A)/oligo (dT)15 as template/primer assessed as decrease in biotin-dUTP incorporation after 1 hr by ELISA | B | 7.7 | pIC50 | 20 | nM | IC50 | Bioorg Med Chem (2018) 26: 2051-2060 [PMID:29559197] |
ChEMBL | Inhibition of HIV1 virion-associated reverse transcriptase | B | 7.7 | pIC50 | 20 | nM | IC50 | Bioorg Med Chem (2008) 16: 6353-6363 [PMID:18502646] |
ChEMBL | Inhibition of HIV1 reverse transcriptase F227L/V106A double mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis | B | 7.7 | pIC50 | 20 | nM | IC50 | Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311] |
ChEMBL | Inhibition of HIV1 reverse transcriptase L100I mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis | B | 7.7 | pIC50 | 20 | nM | IC50 | Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311] |
ChEMBL | Inhibition of recombinant wild-type HIV-1 3B reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis | B | 7.72 | pIC50 | 19 | nM | IC50 | Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935] |
ChEMBL | Inhibition of recombinant wild-type HIV-1 reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli JM109 assessed as reduction in dTTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis | B | 7.72 | pIC50 | 19 | nM | IC50 | Bioorg Med Chem (2017) 25: 3861-3870 [PMID:28559060] |
ChEMBL | Inhibition of HIV1 RT polymerase K103N mutant by SPA | B | 7.72 | pIC50 | 18.9 | nM | IC50 | J Med Chem (2008) 51: 6503-6511 [PMID:18826204] |
ChEMBL | Inhibition of Human immunodeficiency virus 1 subtype B reverse transcriptase DNA-dependent DNA polymerase activity by gel-based primer extension assay | B | 7.74 | pIC50 | 18 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 4667-4672 [PMID:19704127] |
ChEMBL | Inhibition of HIV1 RT mediated DNA-dependent DNA synthesis initiation using RNA PPT primed substrate by scintillation proximity assay | B | 7.77 | pIC50 | 17 | nM | IC50 | J Biol Chem (2007) 282: 8005-8010 [PMID:17172472] |
ChEMBL | Inhibition of wild type HIV-1 reverse transcriptase assessed as assessed as inhibition of biotin deoxyuridine triphosphate incorporation into protein | B | 7.8 | pIC50 | 16 | nM | IC50 | Eur J Med Chem (2023) 247: 115042-115042 [PMID:36577220] |
ChEMBL | Inhibitory concentration against HIV-1 wild type reverse transcriptase (IIIB) | B | 7.85 | pIC50 | 14 | nM | IC50 | J Med Chem (2005) 48: 3858-3873 [PMID:15916438] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of wild type HIV1 reverse transcriptase | B | 7.85 | pIC50 | 14 | nM | IC50 | J Med Chem (2009) 52: 1219-1223 [PMID:19175319] |
ChEMBL | Inhibition of HIV1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into template incubated for 1 hr by ELISA | B | 7.85 | pIC50 | 14 | nM | IC50 | Eur J Med Chem (2019) 182: 111619-111619 [PMID:31434039] |
ChEMBL | Inhibition of HIV1 recombinant wild type reverse transcriptase | B | 7.85 | pIC50 | 14 | nM | IC50 | Bioorg Med Chem (2008) 16: 4173-4185 [PMID:18226533] |
ChEMBL | Inhibition of wild type recombinant HIV-1 reverse transcriptase assessed as reduction of biotin-dUTP incorporation into protein using ABTS as substrate incubated for 1 hrs by ELISA analysis | B | 7.89 | pIC50 | 13 | nM | IC50 | Eur J Med Chem (2023) 247: 115045-115045 [PMID:36577216] |
ChEMBL | Inhibition of HIV1 reverse transcriptase-associated RNA-dependent DNA polymerase activity after 30 mins | B | 7.92 | pIC50 | 12 | nM | IC50 | Eur J Med Chem (2015) 93: 452-460 [PMID:25728026] |
ChEMBL | Inhibition of wild type HIV-1 reverse transcriptase assessed as reduction of biotin-dUTP incorporation into protein using ABTS as substrate incubated for 1 hrs by ELISA analysis | B | 7.96 | pIC50 | 11 | nM | IC50 | Eur J Med Chem (2023) 246: 114957-114957 [PMID:36446205] |
ChEMBL | Inhibition of recombinant wild-type p66/p51 HIV-1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis | B | 7.96 | pIC50 | 11 | nM | IC50 | Eur J Med Chem (2022) 238: 114512-114512 [PMID:35679690] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorometric analysis | B | 7.96 | pIC50 | 11 | nM | IC50 | J Med Chem (2022) 65: 8478-8492 [PMID:35649164] |
ChEMBL | Inhibition of HIV1 isolate R8 reverse transcriptase K103N mutant after 90 mins by electrochemiluminescence analysis | B | 7.99 | pIC50 | 10.2 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 2424-2431 [PMID:19289522] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis | B | 8 | pIC50 | 10 | nM | IC50 | Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311] |
ChEMBL | Inhibition of recombinant wild type p66/p51 HIV1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis | B | 8 | pIC50 | 10 | nM | IC50 | J Med Chem (2022) 65: 2122-2138 [PMID:35073089] |
ChEMBL | Inhibition of HIV1 reverse transcriptase Y181C mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis | B | 8 | pIC50 | 10 | nM | IC50 | Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311] |
ChEMBL | Inhibition of HIV1 wild type reverse transcriptase p66/p51 using poly(rA) template and measured after 40 mins by picogreen based spectrofluorometry | B | 8 | pIC50 | 10 | nM | IC50 | Bioorg Med Chem (2016) 24: 2476-2485 [PMID:27112451] |
ChEMBL | Inhibition of HIV1 reverse transcriptase E138K mutant using oligo(dT)16 as primer measured after 40 mins by picogreen-dye based spectrofluorimetric analysis | B | 8 | pIC50 | 10 | nM | IC50 | Eur J Med Chem (2021) 226: 113868-113868 [PMID:34583311] |
ChEMBL | Inhibition of HIV1 wild type reverse transcriptase expressed in Escherichia coli BL21 (DE3) using [alpha-32P]dATP after 30 mins by liquid scintillation counting | B | 8 | pIC50 | 10 | nM | IC50 | Medchemcomm (2013) 4: 741-748 |
ChEMBL | Inhibition of wild-type HIV1 Reverse transcriptase p51/p66 after 30 mins using alpha-[32P]dATP by liquid scintillation counting | B | 8 | pIC50 | 10 | nM | IC50 | Medchemcomm (2013) 4: 1443-1451 |
ChEMBL | Inhibition of HIV-1 reverse transcriptase assessed as assessed as reduction of biotin-dUTP incorporation into protein incubated for 1 hrs by ELISA analysis | B | 8 | pIC50 | 10 | nM | IC50 | J Med Chem (2023) 66: 8643-8665 [PMID:37255025] |
ChEMBL | Inhibition of HIV1 RT using 17-mer DNA/Alexa Fluor 488 5'-end labeled DNA/Alexa Fluor 555-aha-dUTP as primer/template/substrate preincubated for 10 mins followed substarte addition measured after 30 mins by FRET assay | B | 8 | pIC50 | 10 | nM | IC50 | Bioorg Med Chem Lett (2016) 26: 4101-4105 [PMID:27390064] |
ChEMBL | Inhibition of reverse transcriptase activity in HIV1 infected HeLa-MAGI cells at 37 deg C after 48 hrs | B | 8 | pIC50 | 10 | nM | IC50 | Antimicrob Agents Chemother (2007) 51: 638-644 [PMID:17116672] |
ChEMBL | Inhibition of recombinant wild type p66/p51 HIV1 reverse transcriptase incubated for 40 mins by picogreen dye-based spectrofluorometric analysis | B | 8 | pIC50 | 10 | nM | IC50 | J Med Chem (2021) 64: 5067-5081 [PMID:33851529] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase using [2,8-3H]dGTP as substrate by fluorescence based assay | B | 8 | pIC50 | 10 | nM | IC50 | Eur J Med Chem (2023) 248: 115114-115114 [PMID:36640458] |
ChEMBL | Inhibition of recombinant wild-type HIV1 p66/p51 reverse transcriptase assessed as inhibition of [3H]dGTP incorporation using poly (rA) as templates incubated for 40 mins by spectrofluorometer | B | 8 | pIC50 | 10 | nM | IC50 | J Med Chem (2021) 64: 10297-10311 [PMID:34197708] |
ChEMBL | Inhibition of HIV1 reverse transcriptase Y188C mutant in 293T cells | B | 8.02 | pIC50 | 9.5 | nM | IC50 | Bioorg Med Chem Lett (2006) 16: 3034-3038 [PMID:16527484] |
ChEMBL | Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation into template incubated for 1 hr by ELISA | B | 8.09 | pIC50 | 8.13 | nM | IC50 | Eur J Med Chem (2021) 213: 113051-113051 [PMID:33279288] |
ChEMBL | Inhibition of HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation into template incubated for 1 hr by ELISA | B | 8.09 | pIC50 | 8.1 | nM | IC50 | Eur J Med Chem (2021) 213: 113051-113051 [PMID:33279288] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase assessed as inhibition of biotin-dUTP incorporation into wild type RT measured after 1 hr by ELISA | B | 8.1 | pIC50 | 8 | nM | IC50 | Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378] |
ChEMBL | Inhibition of HIV1 RT polymerase Y181C mutant by SPA | B | 8.14 | pIC50 | 7.2 | nM | IC50 | J Med Chem (2008) 51: 6503-6511 [PMID:18826204] |
ChEMBL | Inhibition of HIV1 reverse transcriptase activity by primer extension assay | B | 8.14 | pIC50 | 7.2 | nM | IC50 | Antimicrob Agents Chemother (2010) 54: 4451-4463 [PMID:20660667] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 using poly(rA)/oligo(dT)16 as template/primer measured after 40 mins by pico-green based spectrofluorometric analysis | B | 8.15 | pIC50 | 7.08 | nM | IC50 | J Med Chem (2019) 62: 2083-2098 [PMID:30721060] |
ChEMBL | Inhibition of recombinant wild type HIV1 reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(A)/oligo(dT)15 as template/primer after 1 hr by ELISA | B | 8.15 | pIC50 | 7 | nM | IC50 | Bioorg Med Chem (2019) 27: 447-456 [PMID:30606670] |
ChEMBL | Inhibition of HIV1 reverse transcriptase p66/p51 using poly(rA)/oligo(dT)16 as template/primer measured after 40 mins by pico-green based spectrofluorometric analysis | B | 8.15 | pIC50 | 7 | nM | IC50 | J Med Chem (2019) 62: 2083-2098 [PMID:30721060] |
ChEMBL | Inhibition of wild-type HIV1 reverse transcriptase infected in human MT4 cells assessed as reduction in biotin-dUTP incorporation | B | 8.22 | pIC50 | 6 | nM | IC50 | ACS Med Chem Lett (2018) 9: 370-375 [PMID:29670703] |
ChEMBL | Inhibition of HIV1 reverse transcriptase Y181C mutant in 293T cells | B | 8.22 | pIC50 | 6 | nM | IC50 | Bioorg Med Chem Lett (2006) 16: 3034-3038 [PMID:16527484] |
ChEMBL | Inhibition of recombinant wild-type HIV1 3B reverse transcriptase assessed as reduction in biotin-dUTP incorporation using poly(rA)/oligo(dT)16 as template primer incubated for 1 hr followed by the addition of (DIG)-dUTP and biotin-labeled dNTPs by ELISA | B | 8.22 | pIC50 | 6 | nM | IC50 | Eur J Med Chem (2019) 176: 11-20 [PMID:31091477] |
ChEMBL | HIV-1 reverse transcriptase inhibitory activity against Cys181 mutant using (poly)rC600*(oligo)dGT as template primer. | B | 8.22 | pIC50 | 6 | nM | IC50 | J Med Chem (1999) 42: 4150-4160 [PMID:10514285] |
ChEMBL | Inhibition of HIV1 reverse transcriptase RNA-dependent DNA polymerase activity assessed as incorporation of radioactive dTTP into poly(rA)/oligo(DT) | B | 8.4 | pIC50 | 4 | nM | IC50 | Bioorg Med Chem (2008) 16: 7429-7435 [PMID:18585918] |
ChEMBL | Inhibition of recombinant wild-type HIV1 GST-fused reverse transcriptase p66/p51 RNA-dependent DNA polymerase activity expressed in Escherichia coli assessed as reduction in biotin-dUTP incorporation using poly(rA)/oligo(dT)16 as template/primer after 40 mins by PicoGreen dye based spectrofluorometric analysis | B | 8.4 | pIC50 | 4 | nM | IC50 | Bioorg Med Chem Lett (2018) 28: 3491-3495 [PMID:30318436] |
ChEMBL | HIV-1 reverse transcriptase inhibitory activity against Wild Type Reverse transcriptase using (poly)rC600*(oligo)dGT as template primer. | B | 8.4 | pIC50 | 4 | nM | IC50 | J Med Chem (1999) 42: 4150-4160 [PMID:10514285] |
ChEMBL | Inhibition of RNA dependent DNA polymerase activity of HIV1 recombinant reverse transcriptase | B | 8.4 | pIC50 | 4 | nM | IC50 | Bioorg Med Chem Lett (2007) 17: 1956-1960 [PMID:17276064] |
ChEMBL | Inhibition of HIV1 recombinant RNA-dependent DNA polymerase activity of reverse transcriptase assessed as incorporation of radioactive dTTP into poly(rA)/oligo(dT) | B | 8.4 | pIC50 | 4 | nM | IC50 | Bioorg Med Chem (2009) 17: 5962-5967 [PMID:19616956] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of HIV1 reverse transcriptase using poly(rA)/pligo(dT) template | B | 8.4 | pIC50 | 4 | nM | IC50 | Bioorg Med Chem (2010) 18: 1702-1710 [PMID:20097079] |
ChEMBL | Concentration required to protect the cell against HIV-1 strain IIIB viral cytopathogenicity by 50% in MT-4 cells | F | 8.4 | pIC50 | 4 | nM | IC50 | Bioorg Med Chem Lett (2004) 14: 3173-3176 [PMID:15149669] |
ChEMBL | Inhibition of RNA-dependent DNA polymerase activity of wild type Human immunodeficiency virus 1 reverse transcriptase | B | 8.52 | pIC50 | 3 | nM | IC50 | Eur J Med Chem (2012) 50: 216-229 [PMID:22361685] |
ChEMBL | Inhibition of recombinant wild type HIV1 reverse transcriptase p66/p51 using poly (rA)/anoligo (dT)16 as template/primer assessed as inhibition of biotin-dUTP incorporation after 40 mins by Pico-Green staining based fluorescence assay | B | 8.7 | pIC50 | 2 | nM | IC50 | Eur J Med Chem (2018) 145: 726-734 [PMID:29353724] |
ChEMBL | Inhibition of wild-type HIV1 reverse transcriptase | B | 8.89 | pIC50 | 1.3 | nM | IC50 | Eur J Med Chem (2009) 44: 2190-2201 [PMID:19058881] |
ChEMBL | Inhibition of wild type Human immunodeficiency virus 1 reverse transcriptase after 30 min by fluorescence microplate reader analysis | B | 8.89 | pIC50 | 1.3 | nM | IC50 | Med Chem Res (2010) 19: 311-336 |
ChEMBL | Inhibition of wild type HIV1 RT polymerase by SPA | B | 9 | pIC50 | 1 | nM | IC50 | J Med Chem (2008) 51: 6503-6511 [PMID:18826204] |
ChEMBL | Inhibition of wild type HIV1 reverse transcriptase in 293T cells | B | 9.1 | pIC50 | 0.8 | nM | IC50 | Bioorg Med Chem Lett (2006) 16: 3034-3038 [PMID:16527484] |
ChEMBL | Inhibitory concentration against wild-type reverse transcriptase of HIV-1 | B | 9.12 | pIC50 | 0.75 | nM | IC50 | J Med Chem (2004) 47: 1175-1182 [PMID:14971897] |
ChEMBL | Inhibition of HIV1 isolate R8 reverse transcriptase after 90 mins | B | 9.38 | pIC50 | 0.42 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 2424-2431 [PMID:19289522] |
ChEMBL | Inhibition of HIV1 isolate R8 reverse transcriptase Y181C mutant after 90 mins by electrochemiluminescence analysis | B | 9.51 | pIC50 | 0.31 | nM | IC50 | Antimicrob Agents Chemother (2009) 53: 2424-2431 [PMID:19289522] |
ChEMBL | Inhibition of HIV1 recombinant reverse transcriptase assessed as incorporation of [32P]GTP into poly(rC).oligo(dG) template primer | B | 9.78 | pIC50 | 0.17 | nM | IC50 | Medchemcomm (2014) 5: 1685-1692 |
ChEMBL | Inhibition of HIV-1BH10 reverse transcriptase expressed in Escherichia coli assessed as polymerization by real time FRET assay | B | 10.04 | pIC50 | 0.09 | nM | IC50 | Eur J Med Chem (2020) 186: 111900-111900 [PMID:31771827] |
ChEMBL | Inhibition of wild type HIV-1 NL4-3 reverse transcriptase using random mRNA as template and GADPH as primer measured at 42 degreeC for 5 mins, 95 degreeC for 10sec and 60 degreeC for 60 sec by qRT-PCR analysis | B | 10.04 | pIC50 | 0.09 | nM | IC50 | Eur J Med Chem (2021) 220: 113498-113498 [PMID:33933756] |
ChEMBL | Inhibition of HIV1 3B reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 6.29 | pEC50 | 514 | nM | EC50 | J Med Chem (2017) 60: 4424-4443 [PMID:28481112] |
ChEMBL | Inhibition of reverse transcriptase F227L/V106A double mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | B | 6.42 | pEC50 | 380 | nM | EC50 | Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378] |
ChEMBL | Inhibition of HIV1 3B reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 6.46 | pEC50 | 348 | nM | EC50 | J Med Chem (2017) 60: 4424-4443 [PMID:28481112] |
ChEMBL | Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 6.51 | pEC50 | 308 | nM | EC50 | J Med Chem (2017) 60: 4424-4443 [PMID:28481112] |
ChEMBL | Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay | F | 6.52 | pEC50 | 300 | nM | EC50 | Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553] |
ChEMBL | Inhibition of reverse transcriptase Y188L mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | B | 6.59 | pEC50 | 260 | nM | EC50 | Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378] |
ChEMBL | Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay | B | 6.65 | pEC50 | 224 | nM | EC50 | ACS Med Chem Lett (2018) 9: 370-375 [PMID:29670703] |
ChEMBL | Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay | F | 6.7 | pEC50 | 200 | nM | EC50 | Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553] |
ChEMBL | Inhibition of reverse transcriptase Y188L mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | B | 6.77 | pEC50 | 171.1 | nM | EC50 | Eur J Med Chem (2020) 202: 112549-112549 [PMID:32712537] |
ChEMBL | Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay | B | 6.8 | pEC50 | 160 | nM | EC50 | Bioorg Med Chem (2017) 25: 2491-2497 [PMID:28314514] |
ChEMBL | Inhibition of recombinant HIV-1 reverse transcriptase RNA-dependent DNA polymerase activity using poly(rA)/oligo(dT)16 as template/primer preincubated for 5 to 10 mins followed by template/primer addition and measured after 16 hrs by colorimetric assay | B | 6.81 | pEC50 | 156.17 | nM | EC50 | Eur J Med Chem (2018) 157: 310-319 [PMID:30099253] |
ChEMBL | Inhibition of HIV1 3B reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 6.94 | pEC50 | 115 | nM | EC50 | J Med Chem (2017) 60: 4424-4443 [PMID:28481112] |
ChEMBL | Inhibition of HIV-1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay | B | 7 | pEC50 | 101 | nM | EC50 | Eur J Med Chem (2016) 122: 185-195 [PMID:27371922] |
ChEMBL | Inhibition of HIV-1 p66/p51 reverse transcriptase K103N mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis | B | 7.04 | pEC50 | 91.5 | nM | EC50 | J Med Chem (2021) 64: 5067-5081 [PMID:33851529] |
ChEMBL | Inhibition of HIV1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 7.1 | pEC50 | 80.1 | nM | EC50 | J Med Chem (2017) 60: 4424-4443 [PMID:28481112] |
ChEMBL | Inhibition of reverse transcriptase K103N mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | B | 7.12 | pEC50 | 76 | nM | EC50 | Eur J Med Chem (2020) 202: 112549-112549 [PMID:32712537] |
ChEMBL | Inhibition of reverse transcriptase K103N mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | B | 7.15 | pEC50 | 71 | nM | EC50 | Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378] |
ChEMBL | Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay | F | 7.24 | pEC50 | 57 | nM | EC50 | Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553] |
ChEMBL | Inhibition of reverse transcriptase F227L/V106A double mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 7.24 | pEC50 | 57 | nM | EC50 | Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935] |
ChEMBL | Inhibition of reverse transcriptase L100I mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | B | 7.32 | pEC50 | 47.5 | nM | EC50 | Eur J Med Chem (2020) 202: 112549-112549 [PMID:32712537] |
ChEMBL | Inhibition of HIV-1 p66/p51 reverse transcriptase L100I mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis | B | 7.35 | pEC50 | 44.7 | nM | EC50 | J Med Chem (2021) 64: 5067-5081 [PMID:33851529] |
ChEMBL | Inhibition of reverse transcriptase K103N/Y181C double mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 7.36 | pEC50 | 44 | nM | EC50 | Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935] |
ChEMBL | Inhibition of reverse transcriptase Y188L mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 7.42 | pEC50 | 38 | nM | EC50 | Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935] |
ChEMBL | Inhibition of HIV1 reverse transcriptase K103N mutant by scintillation counting assay | B | 7.47 | pEC50 | 34 | nM | EC50 | Bioorg Med Chem Lett (2008) 18: 4352-4354 [PMID:18632268] |
ChEMBL | Inhibition of reverse transcriptase L100I mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | B | 7.51 | pEC50 | 31 | nM | EC50 | Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378] |
ChEMBL | Inhibition of reverse transcriptase K103N mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 7.54 | pEC50 | 29 | nM | EC50 | Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935] |
ChEMBL | Inhibition of reverse transcriptase L100I mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 7.8 | pEC50 | 16 | nM | EC50 | Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935] |
ChEMBL | Inhibition of HIV1 3B reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 8.09 | pEC50 | 8.2 | nM | EC50 | J Med Chem (2017) 60: 4424-4443 [PMID:28481112] |
ChEMBL | Inhibition of reverse transcriptase E138K mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | B | 8.15 | pEC50 | 7 | nM | EC50 | Eur J Med Chem (2020) 202: 112549-112549 [PMID:32712537] |
ChEMBL | Inhibition of HIV-1 p66/p51 reverse transcriptase Y181C mutant incubated for 40 mins by picogreen dye-based spectrofluorometric analysis | B | 8.27 | pEC50 | 5.4 | nM | EC50 | J Med Chem (2021) 64: 5067-5081 [PMID:33851529] |
ChEMBL | Inhibition of HIV-1 reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay | B | 8.28 | pEC50 | 5.2 | nM | EC50 | Bioorg Med Chem (2017) 25: 2491-2497 [PMID:28314514] |
ChEMBL | Inhibition of HIV1 3B reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 8.28 | pEC50 | 5.19 | nM | EC50 | J Med Chem (2017) 60: 4424-4443 [PMID:28481112] |
ChEMBL | Inhibition of reverse transcriptase Y181C mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 8.3 | pEC50 | 5 | nM | EC50 | Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935] |
ChEMBL | Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as inhibition of viral replication after 5 days by cell titer glo based luciferase reporter gene assay | B | 8.3 | pEC50 | 5 | nM | EC50 | Eur J Med Chem (2016) 122: 185-195 [PMID:27371922] |
ChEMBL | Inhibition of reverse transcriptase E138K mutant in HIV-1 infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | B | 8.3 | pEC50 | 5 | nM | EC50 | Eur J Med Chem (2021) 214: 113204-113204 [PMID:33567378] |
ChEMBL | Inhibition of reverse transcriptase Y181C mutant in HIV-1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect incubated for 5 days by MTT assay | B | 8.32 | pEC50 | 4.8 | nM | EC50 | Eur J Med Chem (2020) 202: 112549-112549 [PMID:32712537] |
ChEMBL | Inhibition of reverse transcriptase E138K mutant in HIV1 infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay | B | 8.4 | pEC50 | 4 | nM | EC50 | Bioorg Med Chem (2018) 26: 661-674 [PMID:29291935] |
ChEMBL | Concentration required to inhibit HIV-1 reverse transcriptase activity (wild-type) by 50% | B | 8.4 | pEC50 | 4 | nM | EC50 | J Med Chem (2005) 48: 4378-4388 [PMID:15974590] |
ChEMBL | Inhibition of wild-type HIV1 3B reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured 5 days post infection by MTT assay | B | 8.52 | pEC50 | 3 | nM | EC50 | Eur J Med Chem (2018) 158: 371-392 [PMID:30223123] |
ChEMBL | Inhibition of wild-type HIV1 3B reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay | B | 8.55 | pEC50 | 2.85 | nM | EC50 | ACS Med Chem Lett (2018) 9: 370-375 [PMID:29670703] |
ChEMBL | Inhibition of HIV1 reverse transcriptase Y181C mutant by scintillation counting assay | B | 8.7 | pEC50 | 2 | nM | EC50 | Bioorg Med Chem Lett (2008) 18: 4352-4354 [PMID:18632268] |
ChEMBL | Inhibition of HIV1 wild-type reverse transcriptase by scintillation counting assay | B | 9 | pEC50 | 1 | nM | EC50 | Bioorg Med Chem Lett (2008) 18: 4352-4354 [PMID:18632268] |
ChEMBL | Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay | F | 9 | pEC50 | 1 | nM | EC50 | Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553] |
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364] | ||||||||
ChEMBL | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected in human O positive erythrocyte assessed as reduction in parasitemia after 72 hrs | F | 4.36 | pIC50 | 43820 | nM | IC50 | Bioorg Med Chem (2014) 22: 5241-5248 [PMID:25199582] |
CYP3A4 in Human [GtoPdb: 1337] [UniProtKB: P08684] | ||||||||
GtoPdb | Inhibition of CYP3A-mediated conversion of triazolam to 4-OH-triazolam in human liver microsomes. | - | 4.76 | pIC50 | 17500 | nM | IC50 | J Clin Pharmacol (2001) 41: 85-91 [PMID:11225565] |
ChEMBL data shown on this page come from version 34:
Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]